SPARCELLS PHARMA LTD


Directors	F Mohammed
	J M Atlaf


Registered Address	Sparcells Pharmacy Midwinter Close
	Peatmoor
	Swindon
	SN5 5AN


Registered Number	07525024 (England and Wales)

Balance Sheet as at
28 February 2025

	Notes	2025		2024
		£	£	£	£
Fixed assets
Tangible assets	3		3,953		3,117
			3,953		3,117
Current assets
Stocks	4	20,510		18,472
Debtors	5	189,533		174,840
Cash at bank and on hand		139,319		65,107
		349,362		258,419
Creditors amounts falling due within one year	6	(332,698)		(260,894)
Net current assets (liabilities)			16,664		(2,475)
Total assets less current liabilities			20,617		642
Net assets			20,617		642
Capital and reserves
Called up share capital			100		100
Profit and loss account			20,517		542
Shareholders' funds			20,617		642

The company was entitled to exemption from audit for this reporting period under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The Directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.
The directors have chosen to not file a copy of the company’s profit and loss account under section 444 (5A) Companies Act 2006.

The financial statements were approved and authorised for issue by the Board of Directors on 9 October 2025, and are signed on its behalf by:

F Mohammed
Director

J M Atlaf
Director

Registered Company No. 07525024

SPARCELLS PHARMA LTD

Notes to the Financial Statements
for the year ended 28 February 2025

1.	Accounting policies

	Statutory information
	The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

	Statement of compliance
	The financial statements have been prepared in compliance with FRS 102 Section 1A as it applies to the financial statements for the period and there were no material departures from the reporting standard.

	Basis of preparation
	The accounts have been prepared under the historical cost convention and in accordance with FRS 102, the financial reporting standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard).

	Revenue from sale of goods
	Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have transferred to the buyer. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.

Revenue from sale of goods

Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have transferred to the buyer. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.

	Employee benefits
	Contributions to defined contribution plans are expensed in the period to which they relate.

	Current taxation
	Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.

	Tangible fixed assets and depreciation
	Tangible fixed assets are stated at cost or valuation less depreciation. Depreciation is provided on all tangible fixed assets as follows:


		Reducing balance (%)
	Fixtures and fittings	20
	Office Equipment	25

	Stocks and work in progress
	Stocks are valued at the lower of cost and estimated selling price (less any associated costs to enable such sales to complete).

2.	Average number of employees


		2025		2024
	Average number of employees during the year	3		3

3.	Tangible fixed assets

	Fixtures & fittings	Office Equipment	Total
	£	£	£
Cost or valuation
At 01 March 24	57,588	2,655	60,243
Additions	-	1,770	1,770
At 28 February 25	57,588	4,425	62,013
Depreciation and impairment
At 01 March 24	56,427	699	57,126
Charge for year	232	702	934
At 28 February 25	56,659	1,401	58,060
Net book value
At 28 February 25	929	3,024	3,953
At 29 February 24	1,161	1,956	3,117

4.	Stocks

	2025	2024
	£	£
Finished goods	20,510	18,472
Total	20,510	18,472

5.	Debtors: amounts due within one year

	2025	2024
	£	£
Trade debtors / trade receivables	180,746	152,634
Amounts owed by group undertakings	-	5,500
Other debtors	8,448	16,399
Prepayments and accrued income	339	307
Total	189,533	174,840

6.	Creditors: amounts due within one year

	2025	2024
	£	£
Trade creditors / trade payables	117,764	100,137
Amounts owed to related parties	44,000	28,000
Taxation and social security	18,902	14,354
Payments received on account	56,009	47,046
Other creditors	50,101	63,465
Accrued liabilities and deferred income	45,922	7,892
Total	332,698	260,894


	Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.

7.	Related party transactions
	At the year end, the company owed £44,000 (2024: £28,000) to Nias Holdings Ltd. The companies are related as Mr. Mohammed Fahim, a director of the company, is also a director of Nias Holdings Ltd. The company also owed £36,000 (2024: £12,000) to MAJ Locums Ltd. The companies are related as Mr. Muhammad Javed, a director of the company, is also a director of MAJ Locums Ltd.

8.	Controlling party
	The company's ultimate controlling party is F&A Pharma Ltd, by virtue of its 100% shareholding in the company